HIGHLIGHTS
- who: Mingrui Du from the Department of Orthopedics, The Second Affiliated Hospital, The Fourth Military Medical University, Xiu2019an, China have published the Article: Genome-wide CRISPR screen identified Rad18 as a determinant of doxorubicin sensitivity in osteosarcoma, in the Journal: (JOURNAL)
- what: Although chemotherapy improves the prognosis of patients with OS, chemotherapy resistance is still one of the main reasons for treatment failure. The authors systematically evaluated the mechanism driving doxorubicin resistance in OS by genomewide CRISPR/Cas9 knockout screening in OS cells treated with doxorubicin and DMSO (control). To further identify doxorubicin resistance-related . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.